Last reviewed · How we verify
NCT05414643: Team-Shock
Management of Acute Cardiogenic Shock at the New Brunswick Heart Centre
trial testing Standard care in Cardiogenic Shock in 1,416 participants. Completed in 13 October 2021.
13 October 2021
Quick facts
| Lead sponsor | New Brunswick Heart Centre |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,416 |
| Start date | 14 January 2021 |
| Primary completion | 13 October 2021 |
| Estimated completion | 13 October 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Standard care — full drug profile →
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
Sponsor
New Brunswick Heart Centre
Who can join
Eligibility, any sex, with Cardiogenic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Atlantic Canada, acute myocardial infarction occurs at a rate of 2.9 % of the population and is the most common cause of cardiogenic shock (CS). In many studies, acute myocardial infarction accounts for up to 80% of the patients with CS. While there are different methods of treating patients with CS, the rate of mortality has not significantly improved over the years and remains as high as 50%. Recent studies have shown that a multi-modal, team-based approach can help improve patient outcomes; however, such a standardized approach is yet to be implemented in the New Brunswick Heart Centre (NBHC). The study aims to understand the difference in outcomes between two groups of patients treated for CS: SHOCK TEAM versus non-SHOCK TEAM. This is a retrospective study of 168 patients using the data from NBHC registry and patient charts. The study duration is 1 year. The primary outcome is hospital survival. Secondary outcomes include time from diagnosis to invasive monitoring and intervention. All data will be analyzed statistically between the two groups. The end goal of the study is to establish standard guidelines to treat CS patients and improve patient survival.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05414643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard care
Trials testing the same drug.
- NCT04980703 — Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial · NA · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07511868 — Digital Application for Stroke Health · NA · not yet recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
- NCT07376668 — Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery · NA · not yet recruiting
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other New Brunswick Heart Centre trials
Trials by the same sponsor.
- NCT05349708 — Telehealth Home-monitoring for Frailty in Cardiac Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05414643 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Brunswick Heart Centre
- Last refreshed: 10 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05414643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing